Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Hold” from Brokerages

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has received a consensus recommendation of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $22.25.

Several equities analysts recently commented on ACRS shares. BTIG Research restated a “neutral” rating on shares of Aclaris Therapeutics in a research report on Thursday, January 11th. StockNews.com downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 2nd. Cantor Fitzgerald reissued a “neutral” rating on shares of Aclaris Therapeutics in a research note on Friday, January 12th. Finally, HC Wainwright lowered shares of Aclaris Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, January 22nd.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Corton Capital Inc. bought a new position in shares of Aclaris Therapeutics during the 3rd quarter valued at $102,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Aclaris Therapeutics by 42.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,317 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 6,074 shares during the period. Vontobel Holding Ltd. grew its stake in shares of Aclaris Therapeutics by 128.8% during the fourth quarter. Vontobel Holding Ltd. now owns 30,268 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 17,040 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Aclaris Therapeutics in the first quarter worth about $39,000. Finally, SG Americas Securities LLC increased its holdings in shares of Aclaris Therapeutics by 69.5% in the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after buying an additional 13,461 shares during the period. 98.34% of the stock is owned by hedge funds and other institutional investors.

Aclaris Therapeutics Trading Up 2.3 %

ACRS stock opened at $1.34 on Friday. The firm has a 50 day moving average of $1.23 and a 200-day moving average of $1.54. The firm has a market capitalization of $95.49 million, a P/E ratio of -1.06 and a beta of 0.23. Aclaris Therapeutics has a 12 month low of $0.59 and a 12 month high of $11.12.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.07. The business had revenue of $17.57 million for the quarter, compared to analysts’ expectations of $3.96 million. Aclaris Therapeutics had a negative net margin of 283.15% and a negative return on equity of 64.56%. Sell-side analysts predict that Aclaris Therapeutics will post -0.98 EPS for the current year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.